[1]陆晨雅,陈国芳,徐书杭,等.甲状腺相关性眼病处理的新视角:局部注射疗法[J].国际内分泌代谢杂志,2023,43(02):104-108.[doi:10.3760/cma.j.cn121383-20210426-04068 ]
　Lu Chenya,Chen Guofang,Xu Shuhang,et al.Therapy insight: local injections for the treatment of thyroid associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2023,43(02):104-108.[doi:10.3760/cma.j.cn121383-20210426-04068 ]
点击复制

甲状腺相关性眼病处理的新视角:局部注射疗法 ()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年02期
页码:
104-108
栏目:
综述
出版日期:
2023-03-20

文章信息/Info

Title:
Therapy insight: local injections for the treatment of thyroid associated ophthalmopathy
作者:
陆晨雅1; 2; 陈国芳1; 徐书杭1; 刘超1
1南京中医药大学附属中西医结合医院,江苏省中医药研究院内分泌科,南京 210028; 2东阳市中医院内分泌科,东阳 322100
Author(s):
Lu Chenya1; 2;  Chen Guofang1;  Xu Shuhang1;  Liu Chao1.
1Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China; 2Department of Endocrinology, Dongyang Hospital of Traditional Chinese Medicine, Dongyang 322100, China
关键词:
甲状腺相关性眼病;  局部注射治疗;  A型肉毒毒素;  糖皮质激素;  生长抑素类似物;  利妥昔单抗
Keywords:
Thyroid associated ophthalmopathy;  Local injection;  Botulinum toxin type A;  Glucocorticoid;  Somatostatin analog;  Rituximab
DOI:
10.3760/cma.j.cn121383-20210426-04068
摘要:
甲状腺相关性眼病(TAO)是自身免疫性甲状腺疾病的主要外在表现,也是临床治疗的难点。中、重度和活动性TAO的一线方案即大剂量糖皮质激素脉冲治疗的疗效有限且不良反应令人担忧。而眼眶局部注射治疗不仅能够有效改善患者的临床症状,降低TAO的活动性和严重度,且相较于全身用药而言,不良反应更少,可以成为新的治疗选择。A 型肉毒毒素、透明质酸、糖皮质激素、生长抑素类似物和新型生物制剂等多种药物已被尝试用于眼眶局部注射。
Abstract:
Thyroid associated ophthalmopathy(TAO)is the main extrathyroidal manifestation of autoimmune thyroid diseases. It is also very difficult to manage the patients with severe orbital involvement. The high-dose glucocorticoid via the intravenous route is the first-line therapy for moderate-to-severe and active TAO, which is unsatisfied with the limited efficacy and adverse events. Orbital topical injection therapy can not only effectively improve the clinical symptoms and reduce the activity and severity, but also lower the incidence of adverse events compared with systemic administration. Therefore, it can be used as an adjuvant method in the treatment of TAO. Several drugs, including botulinum toxin type A, hyaluronic acid, somatostatin analogs, glucocorticoids, and new immunomodulatory agents, have been tried in orbital topical injection.

参考文献/References:

[1] 甘华侠,朱凌燕,刘峰,等.甲状腺内局部注射免疫调节剂治疗Graves眼病的临床研究[J].实用临床医学,2012,13(10):39-40,50.DOI:10.3969/j.issn.1009-8194.2012.10.015.
[2] Bartalena L,Kahaly GJ,Baldeschi L,et al.The 2021 European Group on Graves' orbitopathy(EUGOGO)clinical practice guidelines for the medical management of Graves' orbitopathy[J].Eur J Endocrinol,2021,185(4):G43-G67.DOI:10.1530/EJE-21-0479.
[3] Gaballa SA,Kompella UB,Elgarhy O,et al.Corticosteroids in ophthalmology:drug delivery innovations,pharmacology,clinical applications,and future perspectives[J].Drug Deliv Transl Res,2021,11(3):866-893.DOI:10.1007/s13346-020-00843-z.
[4] Escuder AG,Hunter DG.The role of botulinum toxin in the treatment of strabismus[J].Semin Ophthalmol,2019,34(4):198-204.DOI:10.1080/08820538.2019.1620795.
[5] Salour H,Bagheri B,Aletaha M,et al.Transcutaneous dysport injection for treatment of upper eyelid retraction associated with thyroid eye disease[J].Orbit,2010,29(2):114-118.DOI:10.3109/01676830903324268.
[6] Costa PG,Saraiva FP,Pereira IC,et al.Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage[J].Eye(Lond),2009,23(4):767-773.DOI:10.1038/eye.2008.165.
[7] 黎冬平,杜芳,李俊萍,等.A型肉毒素治疗甲状腺相关眼病上睑退缩[J].临床眼科杂志,2018,26(6):542-544.DOI:10.3969/j.issn.1006-8422.2018.06.017.
[8] Ozturk Karabulut G,Fazil K,Saracoglu Yilmaz B,et al.An algorithm for botulinum toxin A injection for upper eyelid retraction associated with thyroid eye disease:long-term results[J].Orbit,2021,40(5):381-388.DOI:10.1080/01676830.2020.1814351.
[9] Granet DB,Hodgson N,Godfrey KJ,et al.Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease[J].Graefes Arch Clin Exp Ophthalmol,2016,254(5):999-1003.DOI:10.1007/s00417-016-3281-6.
[10] Akbari MR,Ameri A,Keshtkar Jaafari AR,et al.Botulinum toxin injection for restrictive myopathy of thyroid-associated orbitopathy:success rate and predictive factors[J].J AAPOS,2016,20(2):126-130.e1.DOI:10.1016/j.jaapos.2016.01.007.
[11] Grisolia ABD,Couso RC,Matayoshi S,et al.Non-surgical treatment for eyelid retraction in thyroid eye disease(TED)[J].Br J Ophthalmol,2018,102:158-163.DOI:10.1136/bjophthalmol-2017-310695.
[12] Kohn JC,Rootman DB,Liu W,et al.Hyaluronic acid gel injection for upper eyelid retraction in thyroid eye disease:functional and dynamic high-resolution ultrasound evaluation[J].Ophthalmic Plast Reconstr Surg,2014,30(5):400-404.DOI:10.1097/IOP.0000000000000130.
[13] Hassan Hussien M,Abd El-Wahed Hassan E,El-Haddad NSEM.Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction[J].Ther Adv Ophthalmol,2020,12:1-8.DOI:10.1177/2515841420979113.
[14] Fung AT,Tran T,Lim LL,et al.Local delivery of corticosteroids in clinical ophthalmology:a review[J].Clin Exp Ophthalmol,2020,48(3):366-401.DOI:10.1111/ceo.13702.
[15] Ebner R,Devoto MH,Weil D,et al.Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone[J].Br J Ophthalmol,2004,88(11):1380-1386.DOI:10.1136/bjo.2004.046193.
[16] Hamed-Azzam S,Mukari A,Feldman I,et al.Fornix triamcinolone injection for thyroid orbitopathy[J].Graefes Arch Clin Exp Ophthalmol,2015,253(5):811-816.DOI:10.1007/s00417-015-2957-7.
[17] Bagheri A,Abbaszadeh M,Yazdani S.Intraorbital steroid injection for active thyroid ophthalmopathy[J].J Ophthalmic Vis Res,2020,15(1):69-77.DOI:10.18502/jovr.v15i1.5948.
[18] Xu D,Liu Y,Xu H,et al.Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy[J].Can J Ophthalmol,2012,47(1):34-41.DOI:10.1016/j.jcjo.2011.12.005.
[19] Wang Y,Du B,Yang M,et al.Peribulbar injection of glucocorticoids for thyroid-associated ophthalmopathy and factors affecting therapeutic effectiveness:a retrospective cohort study of 386 cases[J].Exp Ther Med,2020,20(3):2031-2038.DOI:10.3892/etm.2020.8896.
[20] Bordaberry M,Marques DL,Pereira-Lima JC,et al.Repeated peribulbar injections of triamcinolone acetonide:a successful and safe treatment for moderate to severe Graves' ophthalmopathy[J].Acta Ophthalmol,2009,87(1):58-64.DOI:10.1111/j.1755-3768.2008.01171.x.
[21] Gomes-Porras M,Cárdenas-Salas J,Álvarez-Escolá C.Somatostatin analogs in clinical practice:a review[J].Int J Mol Sci,2020,21(5):1682.DOI:10.3390/ijms21051682.
[22] 彭细峰,姜文浩,颜坚,等.激素冲击联合奥曲肽球后注射治疗甲状腺相关眼病[J].国际眼科杂志,2014,14(10):1906-1907.DOI:10.3980/j.issn.1672-5123.2014.10.51.
[23] 石勇铨,刘志民,顾明君,等.免疫抑制剂球后注射治疗甲状腺相关性眼病的疗效和安全性观察[J].上海医学,2004,27(7):473-475.DOI:10.3969/j.issn.0253-9934.2004.07.009.
[24] Lee ACH,Kahaly GJ.Novel approaches for immunosuppression in Graves' hyperthyroidism and associated orbitopathy[J].Eur Thyroid J,2020,9(Suppl 1):17-30.DOI:10.1159/000508789.
[25] Savino G,Balia L,Colucci D,et al.Intraorbital injection of rituximab:a new approach for active thyroid-associated orbitopathy,a prospective case series[J].Minerva Endocrinol,2013,38(2):173-179.
[26] Savino G,Mandarà E,Gari M,et al.Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy[J].Endocrine,2015,48(1):241-247.DOI:10.1007/s12020-014-0283-1.
[27] 张荧钗,徐书杭,刘超.胰岛素样生长因子Ⅰ受体及其在Graves眼病中作用研究进展[J].中华内分泌代谢杂志,2020,36(9):799-802.DOI:10.3760/cma.j.cn311282-20200212-00059.

相似文献/References:

[1]冯周琴,邵加庆,叶小珍.眼眶成纤维细胞异常脂肪分化与甲状腺相关性眼病关系的研究进展[J].国际内分泌代谢杂志,2021,41(01):15.[doi:10.3760/cma.j.cn121383-20200508-05011]
　Feng Zhouqin,Shao Jiaqing,Ye Xiaozhen..Abnormal adipogenesis originated from orbital fibroblasts in thyroid-associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2021,41(02):15.[doi:10.3760/cma.j.cn121383-20200508-05011]
[2]胡晓娜,尹雅琪,谷伟军,等.TRAb水平与甲状腺相关性眼病活动度及严重程度的相关性分析[J].国际内分泌代谢杂志,2022,42(05):334.[doi:10.3760/cma.j.cn121383-20220306-03013]
　Hu Xiaona,Yin Yaqi,Gu Weijun,et al.Correlation between TRAb and thyroid-associated ophthalmopathy activity/severity scores[J].International Journal of Endocrinology and Metabolism,2022,42(02):334.[doi:10.3760/cma.j.cn121383-20220306-03013]

备注/Memo

备注/Memo:
基金项目:江苏省六大人才高峰(WSN-035)
通信作者:刘超,Email:liuchao@nfmcn.com
更新日期/Last Update: 2023-04-15